Bolt Biotherapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
BOLT$6.30-2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Additional · AccumulatedOther · Total | ||||||
|---|---|---|---|---|---|---|
| Common · Paid-In · Comprehensive · Accumulated · Stockholders' | ||||||
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balance at December 31, 2023 | 1,905,750 | $— | $476,989 | $37 | $(364,285) | $112,741 |
| Issuance of common stock upon vesting of restricted stock units | 2,032 | — | — | — | — | — |
| Issuance of common stock under employee stock purchase plan | 9,161 | — | 108 | — | — | 108 |
| Stock-based compensation | — | — | 7,407 | — | — | 7,407 |
| Unrealized gain on available-for-sale investments | — | — | — | 60 | — | 60 |
| Net loss | — | — | — | — | (63,118) | (63,118) |
| Balance at December 31, 2024 | 1,916,943 | $— | $484,504 | $97 | $(427,403) | $57,198 |
| Issuance of common stock under employee stock purchase plan | 3,623 | — | 19 | — | — | 19 |
| Stock-based compensation | — | — | 2,782 | — | — | 2,782 |
| Unrealized loss on available-for-sale investments | — | — | — | (118) | — | (118) |
| Net loss | — | — | — | — | (33,376) | (33,376) |
| Balance at December 31, 2025 | 1,920,566 | $— | $487,305 | $(21) | $(460,779) | $26,505 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.